Apoptosis can be induced by various stimuli including DNA-damaging anticancer drugs and the protein kinase inhibitor staurosporine. It is generally believed that the molecular events during execution of apoptosis are shared, as both anticancer drugs and staurosporine derivatives induce mitochondrial damage, cytochrome c release and the activation of the caspase-9 proteolytic cascade. In the present study we show that overexpression of a dominant-negative caspase-9 mutant abolished the activation of endogenous caspase-9, caspase-3 and the cleavage of the caspase substrate Bid in response to anticancer drug treatment. Surprisingly, however, only marginal eects were observed during staurosporine-induced apoptosis. Furthermore, we describe a Jurkat T-cell clone that is completely resistant towards dierent anticancer drugs, but remains sensitive towards staurosporine-induced apoptosis. In these cells only staurosporine, but neither anti-CD95 nor anticancer drugs were able to trigger caspase activity and the cleavage of caspase substrates. Our results therefore suggest that the mechanism of staurosporine-induced apoptosis is more complex and at least partially diers from anticancer drug-induced caspase activation. These distinct features of staurosporine may allow to bypass chemoresistance of tumor cells and may encourage further clinical trials for the use of staurosporine derivatives in antitumor therapy. Oncogene (2001) 20, 1193 ± 1202.
Introduction
A wide variety of stimuli such as ligands of death receptors, chemotherapeutic drugs and irradiation can induce apoptosis in tumor cells that is mediated by a common cell death machinery. Central for this process is a family of intracellular proteases, known as caspases (Cohen, 1997; Cryns and Yuan, 1998; Los et al., 1999) . All caspases are synthesized as inactive precursors that need to be activated by proteolytic processing. During apoptosis, they can act either as initiators in response to apoptotic signals or as eectors that ®nally cleave a number of vital proteins and lead to the demise of the cell. The activation of caspases is controlled via multiple signaling pathways. One well-described pathway involves the ligation of death receptors, such as CD95, which recruits the FADD adaptor molecule to the receptor complex and in turn triggers the autoproteolytic activation of caspase-8 (Muzio et al., 1996; Boldin et al., 1996; Schulze-Ostho et al., 1998) . Active caspase-8 leads to the proteolytic activation of downstream caspases including the eector caspase-3 and -6. Another death pathway, which is triggered by a number of apoptotic stimuli such as anticancer drugs or irradiation, is initiated by the release of cytochrome c from mitochondria (Liu et al., 1996) . The mitochondrial release of cytochrome c is in part under control of pro-and anti-apoptotic proteins of the Bcl-2 family (Yang et al., 1997; Kluck et al., 1997) . In the cytoplasm cytochrome c associates with Apaf-1, an adaptor molecule that can bind to and activate caspase-9, which in turn activates eector caspases (Li et al., 1997) . Furthermore, the role of the endoplasmic reticulum as a main organelle constituting a third apoptotic pathway has been recently postulated (Nakagawa et al., 2000) , although the relevance of this pathway is still rather unknown.
Many inducers of apoptosis do not act accordingly to a single signaling pathway, but rather rely on the interaction of numerous pathways. Thus, it has been discovered that both the death receptor and mitochondrial pathway are interconnected via the activation of the Bcl-2 protein Bid Luo et al., 1998) . Bid is directly cleaved by caspase-8, whereupon the C-terminal BH3 domain-containing fragment of Bid triggers cytochrome c release. In addition, caspase-8 activation and Bid cleavage can be observed in cells triggered to undergo apoptosis by chemotherapeutic drugs and irradiation (Slee et al., 2000; Tang et al., 2000; Engels et al., 2000; . In this pathway, caspase-8 and Bid are not activated through death receptors, but by a postmitochondrial event, suggesting that in some cases traditional initiator caspases may also act as eectors of apoptosis.
Whereas the signaling cascades of death receptormediated caspase activation are relatively well understood, the molecular mechanisms by which anticancer drugs trigger apoptosis are controversial. Most agents used in cancer therapy lead to DNA damage or interfere with DNA replication and synthesis. However, it is almost completely unknown which signaling events following nuclear action of these drugs lead to caspase activation. It has been postulated that chemotherapeutic drugs induce the expression of CD95 and CD95L, which may trigger a paracrine or autocrine loop of apoptosis via CD95/CD95L interaction (Friesen et al., 1996; Fulda et al., 1997; MuÈ ller et al., 1997; Herr et al., 1998) . However, most recent reports support the idea that anticancer druginduced apoptosis is mediated by the mitochondrial caspase cascade independently of death receptors Wesselborg et al., 1999; Eischen et al., 1997; Gamen et al., 1997; Villunger et al., 1997; Kataoka et al., 1998) . One widely accepted, albeit not general process is the drug-induced activation of Bax expression, which is a key event for p53-mediated cell death that triggers the release of cytochrome c from mitochondria in a Bcl-2-controlled manner (Miyashita and Reed, 1995; Rosse et al., 1998) .
A frequently used agent for the induction of apoptosis is staurosporine. The substance has been originally isolated from Streptomyces, and since then several new derivatives have been synthesized for clinical trials in anticancer therapies (Gescher, 1998) . Although staurosporine has been ®rst described as an inhibitor of protein kinase C, it has become clear that it is a nonselective inhibitor of a diverse array of dierent kinases (Ruegg and Burgess, 1989; Meggio et al., 1995) . One unique property of staurosporine is its ability to rapidly and completely drive virtually all mammalian cells into apoptosis. Staurosporine-induced apoptosis involves mitochondrial caspase activation that is inhibited by Bcl-2 (Bertrand et al., 1994; Jacobson et al., 1994 Jacobson et al., , 1996 Takahashi et al., 1997) . However, despite its widespread use, the primary site of action of staurosporine in apoptosis induction is unknown.
In the present study, we compared apoptosis and caspase activation induced by staurosporine, conventional anticancer drugs and CD95 ligation. We provide evidence that, although staurosporine-induced apoptosis is mediated by the mitochondrial caspase cascade, it diers from anticancer drug-induced cell death in certain aspects. The dierence of caspase activation between DNA-damaging anticancer drugs and staurosporine suggests that a combined use of these agents may be of therapeutic bene®t to overcome drug resistance in tumor cells.
Results

Induction of apoptosis, caspase-8 activation and Bid cleavage by conventional anticancer drugs and staurosporine
It is well established that agonistic anti-CD95 antibodies, anticancer drugs and staurosporine are potent stimuli of apoptosis in a variety of cell lines. In Jurkat T-leukemic cells all agents strongly induced apoptosis as measured by¯ow cytometry of hypodiploid DNA (Figure 1a) . Induction of apoptosis was completely inhibited by the broad caspase inhibitor zVAD ( Figure  1b) , indicating a common eector pathway induced by all apoptotic stimuli. Apoptosis was also induced in L929 ®brosarcoma cells stably transfected with CD95. However, whereas anti-CD95 and staurosporine induced apoptosis in more than 50% of the cells, only weak eects were observed in L929 cells following incubation with anticancer drugs, such as the topoisomerase inhibitor etoposide and the DNA-intercalating drug mitomycin C (Figure 1a ). This indicates that cells possess dierent susceptibilities towards staurosporine and conventional anticancer drugs.
The activation of caspase-8 and the subsequent proapoptotic cleavage of Bid are important events in apoptosis induction by death receptors. We and others have previously reported that also anticancer drugs can induce caspase-8 activation independently of death receptors (Engels et al., 2000; Slee et al., 2000; Tang et al., 2000) . In this scenario, caspase-8 activation occurs downstream of cytochrome c release and functions as an amplifying eector mechanism of the mitochondrial caspase cascade. As shown in Figure 2a , anti-CD95 and etoposide induced caspase-8 processing with dierent kinetics and intensities. Cleavage of the two caspase-8 precursors, procaspase-8a and -8b, into the p43/41 intermediate fragments occured in less than 3 h after anti-CD95 stimulation and required more than 6 h after stimulation of cells with etoposide. Moreover, staurosporine was also able to rapidly and completely process procaspase-8 within a similar time course as anti-CD95. The activation of caspase-8 in response to all three stimuli was inhibited by the caspase inhibitor zVAD (Figure 2a) .
Like anti-CD95, all agents were also able to induce caspase-dependent Bid cleavage (Figure 2b ). The cleavage of Bid promotes its translocation to the mitochondrial membrane and induces cytochrome c release. Anti-CD95 and staurosporine rapidly induced Bid activation, as indicated by the loss of its p26 proform. In response to stimulation with etoposide, the processing of Bid was delayed, although it was clearly detectable (Figure 2b ).
In addition to immunoblot analysis, the activation of caspases was determined by¯uorogenic substrate assays. Staurosporine rapidly triggered the cleavage of a LEHD-containing peptide, a preferential substrate of caspase-9 ( Figure 3a ). As measured by the cleavage of DEVD-AMC, also a stimulation of caspase-3-like activity was observed that was rapid but slightly delayed in comparison to caspase-9 ( Figure 3b ). In contrast to staurosporine, the activation of both caspase-9 and caspase-3-like activities in response to daunorubicin and etoposide was less intense and required longer incubation times to occur.
Staurosporine can override the inhibitory signal exerted by dominant-negative mutants of caspase-9 and cause caspase and Bid activation Since caspase-9 is the most apical caspase in the mitochondrial pathway of apoptosis, we used a dominant-negative mutant of caspase-9 (caspase- 6 Jurkat cells were incubated in the presence or absence of 100 mM zVAD for 1 h and subsequently stimulated for the indicated times with anti-CD95 (upper panels), etoposide (middle panels) or staurosporine (lower panels). Cellular proteins were separated by SDS ± PAGE, and the proteolytic processing of caspase-8 (a) and Bid (b) was detected by immunoblotting. Open arrowheads indicate the uncleaved and closed arrowheads the cleaved form of the indicated proteins 9DN), in which the cysteine in the catalytic center was substituted by an alanine residue (C287A). This inactive caspase-9 mutant was stably expressed in Jurkat cells and the eects on apoptosis were subsequently analysed. Stimulation of vector control Jurkat cells with anti-CD95, etoposide and staurosporine triggered the processing of caspase-9 and the appearance of its p35 intermediate fragment, as detected with an activation-speci®c caspase-9 antibody ( Figure 4a ). The overexpression of caspase-9DN resulted in the inhibition of endogenous caspase-9 processing in etoposide-stimulated cells. Interestingly, following stimulation with staurosporine endogenous caspase-9 was still strongly processed despite the presence of the dominant-negative caspase-9 mutant ( Figure 4a ). This dierence was not due to dierences in drug concentrations, because, as determined by dose-dependent titration experiments , all drugs were used at concentrations inducing maximal caspase activation and apoptosis.
Active caspase-9 is able to activate the downstream eector caspase-3 and caspase-6. Consequently, we were able to detect proteolytic processing of caspase-3 in lysates of anti-CD95-, etoposide-and staurosporinestimulated vector control Jurkat cells (Figure 4a ). In cells overexpressing the inactive caspase-9 mutant, caspase-3 processing was inhibited following treatment with etoposide. However, similar as in anti-CD95 treated cells, the presence of caspase-9DN did not interfere with caspase-3 activation by staurosporine (Figure 4a ). This indicated that staurosporine may induce additional ways of caspase activation when compared to conventional anticancer drugs.
Next, we investigated whether staurosporine diers in the way of action from other apoptosis inducers with regard to Bid activation. Immunoblot analyses revealed that all agents used were eective in cleaving the protein in vector control cells (Figure 4a ). In caspase-9DN cells Bid cleavage was considerably reduced in response to etoposide, while staurosporine was still able to strongly trigger Bid cleavage in the presence of catalytically inactive caspase-9 (Figure 4a ). 6 Jurkat cells expressing the vector alone (Vector) or a dominant-negative mutant of caspase-9 (Caspase-9DN), in which the active cysteine was mutated into an alanine (C287A), were stimulated with medium (Control; 6 h), anti-CD95 (a-CD95; 1 mg/ml; 3 h), etoposide (Etopo; 25 mg/ml; 6 h) or staurosporine (Stauro; 2.5 mM, 6 h). Cellular proteins were separated by SDS ± PAGE, and proteolytic processing of caspase-9, caspase-3 and Bid was determined by immunoblotting. The upper part of the caspase-9 blot shows a nonspeci®c immunoreactive protein (NS) that served as control for equal protein loading. (b) Stable transfectants of HeLa cells expressing GFP alone (Vector) or a chimeric dominant-negative caspase-9 mutant, consisting of the CARD of caspase-9 fused to GFP (DCaspase-9), were treated as described in (a) and analysed for the activation of caspase-8. Open arrowheads indicate the uncleaved and closed arrowheads the cleaved form of the indicated proteins Additional evidence for the unique way of staurosporine action was provided by experiments with HeLa cells, which stably expressed a dominant-negative version of caspase-9 containing only its CARD domain fused to a GFP construct. Stimulation of parental HeLa cells with anti-CD95, etoposide and staurosporine activated caspase-8, while the overexpression of the mutant caspase-9 construct impaired caspase-8 activation by anti-CD95 and etoposide, but not by staurosporine (Figure 4b ). This again showed that staurosporine-induced caspase activation diers from the pathways triggered by conventional anticancer drugs.
Jurkat JM319 subclone, while cross-resistant to anti-CD95 and anticancer drug-induced apoptosis, is sensitive to staurosporine By continuous culture in the presence of anti-CD95 we generated a Jurkat cell clone, called JM319, which was completely resistant towards CD95-mediated apoptosis. Figure 5a shows that even high concentrations of anti-CD95 were unable to induce apoptosis in these cells. As revealed by FACS analysis (Figure 6 ), this resistance, however, was not caused by downregulation of CD95 expression, indicating that the blockade of apoptosis was presumably due to a downstream defect. In support of this assumption, the chemotherapeutic drugs etoposide and daunorubicin were unable to induce apoptosis in the JM319 Jurkat subclone (Figure  5b,c) . In JM319 cells also apoptosis induction by low doses of staurosporine was reduced when compared to parental JE6.1 Jurkat cells. Surprisingly, however, staurosporine concentrations higher than 1 mM could still potently induce apoptosis in the drug-resistant clone (Figure 5d) . A similar pattern of drug sensitivity and resistance was observed when membrane damage and cell death were measured by the uptake of propidium iodide (Figure 5e ). Thus, staurosporine proved to be the only agent capable of inducing JM319 cell death to comparable levels as in parental JE6.1 Jurkat cells.
In order to determine the induction of caspase activity in response to the dierent apoptotic stimuli, we incubated cell lysates from Jurkat JM319 and the parental cells with DEVD-AMC and VEID-AMC, twō uorogenic substrates for caspase-3 and caspase-6, respectively. All agents strongly induced caspase-3-and caspase-6-like activities in the parental cells, although the extent of caspase activity slightly diered between anti-CD95, anticancer drugs and staurosporine (Figure 7a ). In the resistant JM319 cells, however, only staurosporine led to a strong induction of caspase activity, while anti-CD95, etoposide and daunorubicininduced caspase activities were signi®cantly impaired.
These data were further veri®ed by immunoblot analyses. In parental JE6.1 cells all agents induced the proteolytic processing of caspase-3 into the active p17 subunit (Figure 7b) . In JM319 cells, however, only staurosporine was able to trigger caspase-3 activation. A similar pattern was observed when the cleavage of the caspase-3 substrate a-fodrin was investigated. In parental cells all stimuli induced the processing of fulllength fodrin to the caspase-3-speci®c p150 fragment, whereas in the resistant clone only staurosporine could trigger fodrin cleavage. Interestingly, only weak dierences among the stimuli were observed when JM319 cells were investigated for Bid cleavage ( Figure  7b ). The processing of Bid in response to staurosporine was also strongly reduced in JM319 cells but not fully prevented. In conclusion, both the experiments employing a dominant-negative caspase-9 mutant as well as the result with the drug-and CD95-resistant Jurkat clone indicate that the pathways of caspase activation and apoptosis dier between conventional anticancer drugs and staurosporine.
Discussion
Staurosporine is a broad-spectrum protein kinase inhibitor that has been used extensively to induce apoptosis in a variety of cells including tumor cells, lymphocytes, neurons and other primary and transformed cell types (Bertrand et al., 1994; Jacobson et al., 1994 Jacobson et al., , 1996 Krohn et al., 1998; Han et al., 2000) . Despite its widespread use the mechanism by which staurosporine induces cell death is unknown. It is generally accepted that like conventional chemotherapeutic drugs staurosporine activates a central component of the apoptotic machinery, since it induces a rapid, macromolecular synthesis-independent death in various cell types (Bertrand et al., 1994) . Consistently, it has been shown that staurosporine-induced cell death is inhibited by Bcl-2 overexpression, involves the release of cytochrome c and results in caspase activation (Jacobson et al., 1994 (Jacobson et al., , 1996 . In the present paper we show that staurosporine and chemotherapeutic drug-induced caspase activation, however, dier in certain aspects.
Because caspase-9 is the central mediator of the mitochondrial branch of caspase activation, we overexpressed a catalytically inactive caspase-9 mutant. As expected, in Jurkat cells expressing this dominantnegative construct, activation of endogenous caspase-9 in response to conventional anticancer drugs, such as etoposide, was inhibited. Furthermore, caspase-9DN expression inhibited the subsequent cleavage of caspase-3 and Bid indicating that the mutant was functionally active. However, the presence of the caspase-9 mutant did not interfere with the activation of these molecules in response to staurosporine treatment.
The failure of a catalytically inactive caspase-9 mutant to inhibit staurosporine-induced caspase activation was also observed with an unrelated caspase-9 mutant construct. To this end, we stably transfected HeLa cells with a truncated caspase-9 construct consisting only of the CARD domain fused to GFP. Overexpression of this mutant inhibited the activation of caspase-8 in response to etoposide, but clearly did not prevent staurosporine-induced caspase-8 proces- In addition to the activation of apical caspases, we observed that staurosporine could still activate caspase-3 and the cleavage of caspase substrates in JM319 Jurkat cells. This Jurkat subclone was largely resistant to other proapoptotic stimuli, as anti-CD95, etoposide and daunorubicin were not able to activate caspase-3. The exclusive activation of caspase-3 by staurosporine corresponded to the induction of apoptosis. In contrast to the parental Jurkat cells that were sensitive to all apoptotic inducers, JM319 cells were resistant to anti- 6 Jurkat JE6.1 and JM319 cells cells were stimulated with anti-CD95 (1 mg/ml, 4 h), staurosporine (2.5 mM, 4 h), etoposide (25 mg/ml, 8 h) or daunorubicin (0.5 mg/ml, 12 h). Cellular lysates were then prepared and incubated with the¯uorogenic substrates DEVD-AMC for caspase-3 and VEID-AMC for caspase-6, respectively. The catalytic activities are given in relative light units (RLU). (b) Eect on caspase and caspase substrate cleavage. Lysates of cells treated as described in (a) were subjected to immunoblotting with caspase-3, a-fodrin and Bid-speci®c antibodies. The open arrowhead indicates the uncleaved and the closed arrowhead the cleaved fragments of the respective protein CD95 and conventional chemotherapeutic drugs, but remained sensitive to staurosporine. Although in these cells apoptosis was impaired at low concentrations of staurosporine, higher concentrations which are commonly used in apoptosis assays led to potent induction of cell death. Noteworthy, it has been recently reported that also the absence of Apaf-1 does not fully prevent apoptosis in response to staurosporine treatment, although Apaf-1-de®cient cells are completely protected against various other classical proapoptotic stimuli (Haraguchi et al., 2000) .
It is currently unknown why staurosporine can induce caspase activation in the presence of an overexpressed caspase-9DN mutant and why it can override the chemoresistance of JM319 cells. Conventional chemotherapeutic drugs mostly interfere with nuclear DNA synthesis and repair processes. In many, yet not all cases, this type of cell death is p53-dependent and mediated by p53-induced expression of Bax (Miyashita and Reed, 1995) . In contrast, staurosporine presumably induces apoptosis by targeting a cytoplasmic regulator of cell death. Thus, we and others have reported that, similar to death receptors, also staurosporine-induced apoptosis does not require nuclear signaling and can even proceed in enucleated cells (Schulze-Ostho et al., 1994; Jacobson et al., 1994) .
There are multiple kinases involved in survival signaling which may be targeted by staurosporine. Members of the PKC family have been associated with apoptosis protection. For instance, inhibition of PKC signaling promotes anti-CD95 signaling in Jurkat cells (Drew et al., 1998) , whereas activation of PKC reduces the cleavage of Bid in CD95-stimulated cells (Scadi et al., 1999) . However, there is also evidence that staurosporine-induced apoptosis is independent of PKC inhibition (Han et al., 2000) . Recently, it has been found that staurosporine inhibits IkB kinase, which is the central regulator of transcription factor NF-kB activation (Peet and Li, 1999) . Since NF-kB induces the synthesis of several anti-apoptotic proteins such as Bcl-x L , A1, A20 and caspase inhibitors of the IAP family (Barkett and Gilmore, 1999) , inhibition of this pathway may contribute to apoptosis induction. A prime candidate as the target of staurosporine is the protein kinase Akt/PKB which may inhibit apoptosis at several levels of the caspase cascade (Masure et al., 1999) . It has been reported that Akt phosphorylates and thereby inactivates caspase-9 (Cardone et al., 1998) , although the general validity of this mechanism has been recently questioned (Fujita et al., 1999) . Akt, however, is the major kinase which phosphorylates the proapoptotic Bcl-2 member Bad and thereby converts Bad into an anti-apoptotic form that does not induce cytochrome c release (Datta et al., 1997; del Peso et al., 1997) .
It is remarkable that JM319 cells underwent apoptosis in response to staurosporine, although they were completely resistant to both CD95 and chemotherapeutic drug-induced apoptosis and did not reveal downregulation of CD95 surface expression.
Interestingly, in contrast to the parental cells, JM319 cells did not cleave Bid in response to all apoptotic stimuli. In the drug-resistant cells also staurosporine only induced a minor cleavage of Bid. It may therefore be speculated that JM319 cells have a defect located at or upstream of Bid signaling. CD95-induced apoptosis requires the activation of Bid for cytochrome c release in so-called type II cells that are dependent on the mitochondrial caspase cascade (Scadi et al., 1998) . Moreover, Bid facilitates the insertion of Bax into the outer mitochondrial membrane following its induction by chemotherapeutic drugs (Eskes et al., 2000) . In contrast, staurosporine-induced apoptosis may be independent of Bid/Bax interaction, as inhibition of Bad phosphorylation by staurosporine and its association with Bcl-x L may be sucient to induce cytochrome c release. Further studies will therefore have to delineate the molecular defect that is responsible for the apoptosis resistance of JM319 cells. In this regard, it will be interesting to investigate whether recombinant Bid or Bax are still able to induce the release of cytochrome c or other mitochondrial proapoptotic components in lysates from JM319 cells.
In summary, it is likely that staurosporine induces apoptosis by multiple pathways and that the inhibition of more than one kinase is responsible for its potent activity. Because, as our results imply, the mechanism of action of staurosporine is distinct from traditional anticancer drugs, this may warrant further preclinical evaluations of the antitumor potential of new staurosporine derivatives either alone or in combination with death ligands or conventional chemotherapeutic drugs.
Materials and methods
Cells and reagents
The acute T-lymphoblastic leukemia cell line Jurkat, the cervix carcinoma cell line HeLa and L929 ®brosarcoma cells stably transfected with CD95 were cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum, 100 units of penicillin/ml, 0.1 mg streptomycin/ml and 10 mM HEPES (all from Gibco ± BRL, Eggenstein, Germany). Cells were grown at 378C in a 5% CO 2 atmosphere and maintained in the log phase. The CD95-resistant Jurkat clone JM319 clone was generated by culture of the parental cell line JE6.1 in the presence of anti-CD95 antibody (Janssen et al., 1996) . Cells surviving under these conditions for at least 14 days were cloned by limiting dilution at 0.3 cells per well. The broad-range caspase inhibitor benzyloxycarbonyl-Val-AlaAsp-¯uoromethylketone (zVAD) was purchased from Enzyme Systems (Dublin, CA, USA) and staurosporine from Roche Molecular Biochemicals (Mannheim, Germany). Anti-CD95 monoclonal antibodies were obtained from BioCheck (MuÈ nster, Germany), Kamiya Biomedical Company (Thousand Oaks, CA, USA) or Becton Dickinson (Heidelberg, Germany). The chemotherapeutic drugs etoposide, daunorubicin and mitomycin C were obtained from the clinical pharmacy (Medical Clinics, TuÈ bingen, Germany). Mitomycin C and daunorubicin were dissolved in methanol, while etoposide was dissolved in ethanol.
Measurement of cell death
For determination of apoptosis, 3610 4 cells per well were seeded in microtiter plates and treated for the indicated time with dierent concentrations of anti-CD95, chemotherapeutic drugs or staurosporine. The leakage of fragmented DNA from apoptotic nuclei was measured by the method of Nicoletti et al. (1991) . Brie¯y, apoptotic nuclei were prepared by lysing cells in a hypotonic lysis buer (0.1% sodium citrate, 0.1% Triton X-100, 50 mg/ml propidium iodide) and subsequently analysed by¯ow cytometry. Nuclei to the left of the 2N peak containing hypodiploid DNA were considered as apoptotic. Cell death was also assessed by the uptake of propidium iodide (2 mg/ml; Sigma) in PBS into non®xed cells and subsequent¯ow cytometric analysis using the FSC/FL2 pro®le. All¯ow cytometric analyses were performed on a FACScalibur (Becton Dickinson) using CellQuest analysis software.
Cell extracts and immunoblotting
Cleavage of caspases and the caspase substrates a-fodrin and Bid was detected by immunoblotting. 2610 6 cells were seeded in 24-well plates and treated with the respective apoptotic stimuli. After the indicated time periods, cells were washed in cold PBS and lysed in 1% Triton X-100, 50 mM Tris, pH 7.6 and 150 mM NaCl containing 3 mg/ml aprotinin, 3 mg/ml leupeptin, 3 mg/ml pepstatin A and 2 mM phenylmethylsulfonyl¯uoride (PMSF). Subsequently, proteins were separated under reducing conditions on a SDS ± polyacrylamide gel and electroblotted to a polyvinylidene di¯uoride membrane (Amersham, Braunschweig, Germany). Membranes were blocked for 1 h with 5% non-fat dry milk powder in TBS and then immunoblotted for 1 h with a rabbit polyclonal antibody against active caspase-9 (Cell Signaling, Frankfurt, Germany), mouse mAbs directed against caspase-8 (BioCheck), caspase-3 (Transduction Laboratory, Heidelberg, Germany), a-fodrin (Sigma, Deisenhofen, Germany) or rat anti-Bid polyclonal antibody (kindly provided by J Yuan, Boston, MA, USA). Membranes were washed four times with TBS/0.02% Triton X-100 and incubated with the respective peroxidase-conjugated anity-puri®ed secondary antibody for 1 h. Following extensive washing, the reaction was developed by enhanced chemiluminescent staining using ECL reagents (Amersham).
Fluorimetric assay of caspase activity
Cytosolic cell extracts were prepared by lysing cells in a buer containing 0.5% NP-40, 20 mM HEPES pH 7.4, 84 mM KCl, 10 mM MgCl 2 , 0.2 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 5 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin and 1 mM PMSF. Caspase activities were determined by incubation of cell lysates with 50 mM of thē uorogenic substrates DEVD-AMC (N-acetyl-Asp-Glu-ValAsp-aminomethylcoumarin), LEHD-AMC (N-acetyl-LeuGlu-His-Asp-aminomethylcoumarin) or VEID-AMC (N-acetyl-Val-Glu-Val-Asp-aminomethylcoumarin; all from Bachem, Heidelberg, Germany) in 200 ml buer containing 50 mM HEPES pH 7.3, 100 mM NaCl, 10% sucrose, 0.1% CHAPS and 10 mM DTT. The release of aminomethylcoumarin was measured by¯uorometry using an excitation wavelength of 360 nm and an emission wavelength of 475 nm.
Cell transfections
An expression vector encoding a dominant-negative caspase-9 mutant, in which the active cysteine was mutated to an alanine (C287A), was kindly provided by ES Alnemri (The Kimmel Cancer Institute, Philadelphia, PA, USA). Electroporation was performed using a Gene pulser II electroporator (Biorad, Munich, Germany). Brie¯y, 10 8 Jurkat cells were washed twice in TBS buer pH 7.4 prior to transfection. Twenty-®ve mg of DNA was electroporated with 135 mF and 500 V. Jurkat cells were selected with 800 mg/ml G418 (Clontech, Heidelberg, Germany). The parental plasmid pcDNA-3 (Invitrogen, Leek, Netherlands) was used as a vector control. Protein expression was monitored by immunoblotting. A construct encoding a dominant-negative fusion protein of the caspase-9 prodomain (amino acids 1 ± 163) and GFP (pCasp9-GFP) was cloned by polymerase chain reaction into the EcoRI and BamHI sites of pEGFP-N1 (Clontech) (Engels et al., 2000) . HeLa cells stably overexpressing Casp9-GFP were generated by transfection with Superfect (Qiagen, Hilden, Germany) and subsequently selected in 600 mg/ml G418. After 2 weeks 100 ± 200 individual colonies were pooled, expanded and enriched for high expression by¯ow cytometry and cell sorting. HeLa cells stably overexpressing the GFP control have been described previously (Wajant et al., 1998) .
